Targeting lymph nodes to improve melanoma immunotherapy
Lymph Node-Targeted Codelivery of Albumin-Binding Peptide Antigens and Di-Adjuvant for Melanoma Combination Immunotherapy
This study is looking to make melanoma treatment better by creating a new type of vaccine that helps your immune system recognize and fight the cancer more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10916544 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of immunotherapy for melanoma, a serious skin cancer. It aims to develop a peptide vaccine platform that delivers tumor-associated antigens directly to lymph nodes and antigen-presenting cells, improving the immune response. By using a method called albumin hitchhiking, the study seeks to overcome challenges in vaccine delivery and enhance the immunogenicity of the treatment. The approach also includes co-delivery of potent adjuvants to boost the immune response against melanoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced melanoma who have not responded to standard immunotherapy treatments.
Not a fit: Patients with early-stage melanoma or those who have not been diagnosed with melanoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for melanoma patients who currently do not respond to existing immunotherapies.
How similar studies have performed: Other research has shown promise in using targeted delivery methods for immunotherapy, suggesting that this approach could be effective.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Zhu, Guizhi — University of Michigan at Ann Arbor
- Study coordinator: Zhu, Guizhi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.